These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 9890122)

  • 1. Diagnosis of obsessive-compulsive illness.
    Rothenberg A
    Psychiatr Clin North Am; 1998 Dec; 21(4):791-801, vi. PubMed ID: 9890122
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of tryptophan depletion on selective serotonin reuptake inhibitor-remitted patients with obsessive compulsive disorder.
    Hood SD; Broyd A; Robinson H; Lee J; Hudaib AR; Hince DA
    J Psychopharmacol; 2017 Dec; 31(12):1615-1623. PubMed ID: 29095069
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Obsessive-compulsive disorder: a concealed diagnosis.
    Nymberg JH; Van Noppen B
    Am Fam Physician; 1994 Apr; 49(5):1129-37, 1142-4. PubMed ID: 8154402
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment response and redefining diagnostic boundaries.
    Hollander E
    CNS Spectr; 2008 Dec; 13(12):1020-1. PubMed ID: 19179937
    [No Abstract]   [Full Text] [Related]  

  • 5. Tourette syndrome. Neuropsychological tests for obsessive-compulsive disorder and attention deficit hyperactivity disorder.
    Como PG
    Neurol Clin; 1997 May; 15(2):255-65. PubMed ID: 9115459
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Selective serotonin reuptake inhibitors, and serotonin and norepinephrine reuptake inhibitors for anxiety, obsessive-compulsive, and stress disorders: A 3-level network meta-analysis.
    Gosmann NP; Costa MA; Jaeger MB; Motta LS; Frozi J; Spanemberg L; Manfro GG; Cuijpers P; Pine DS; Salum GA
    PLoS Med; 2021 Jun; 18(6):e1003664. PubMed ID: 34111122
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Resistant Obsessive Compulsive disorder (ROC): clinical picture, predictive factors and influence of affective temperaments].
    Hantouche EG; Demonfaucon C
    Encephale; 2008 Dec; 34(6):611-7. PubMed ID: 19081459
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Obsessive disorders and syndromes and affective disorders. Apropos of a French epidemiologic obsessive compulsive disorders and obsessive compulsive syndromes DRT survey].
    Bourgeois M
    Encephale; 1996 May; 22 Spec No 1():23-31. PubMed ID: 8767024
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Use of factor-analyzed symptom dimensions to predict outcome with serotonin reuptake inhibitors and placebo in the treatment of obsessive-compulsive disorder.
    Mataix-Cols D; Rauch SL; Manzo PA; Jenike MA; Baer L
    Am J Psychiatry; 1999 Sep; 156(9):1409-16. PubMed ID: 10484953
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impulse control disorders in patients with obsessive-compulsive disorder.
    Fontenelle LF; Mendlowicz MV; Versiani M
    Psychiatry Clin Neurosci; 2005 Feb; 59(1):30-7. PubMed ID: 15679537
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Exacerbation of obsessive-compulsive disorder, generalized anxiety disorder, and chronic motor tics during treatment of attention-deficit/hyperactivity disorder: medication management in an older adolescent.
    Anam PS; Coffey DB
    J Child Adolesc Psychopharmacol; 2013 Oct; 23(8):577-82. PubMed ID: 24138012
    [No Abstract]   [Full Text] [Related]  

  • 12. Obsessive compulsive disorder is not an anxiety disorder.
    Montgomery SA
    Int Clin Psychopharmacol; 1993 Sep; 8 Suppl 1():57-62. PubMed ID: 8254154
    [No Abstract]   [Full Text] [Related]  

  • 13. Psychometric Properties of a Structured Diagnostic Interview for DSM-5 Anxiety, Mood, and Obsessive-Compulsive and Related Disorders.
    Tolin DF; Gilliam C; Wootton BM; Bowe W; Bragdon LB; Davis E; Hannan SE; Steinman SA; Worden B; Hallion LS
    Assessment; 2018 Jan; 25(1):3-13. PubMed ID: 26988404
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Obsessive compulsive disorder (OCD)].
    Debabèche C; Muselle A; Servais S; Farcy L; Barbier V; Laloyaux C; Mikolajczak G; Desseilles M
    Rev Med Suisse; 2009 Aug; 5(214):1659-62. PubMed ID: 19772197
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Breakthrough in psychiatric care: pharmacological treatment of obsessive-compulsive disorders with implications for nursing care.
    Giger JN; Davidhizar R; Poole VL
    J Pract Nurs; 2002; 52(2):12-6; quiz 17, 21. PubMed ID: 12122747
    [No Abstract]   [Full Text] [Related]  

  • 16. Effects of selective serotonin reuptake inhibitors on thought-action fusion, metacognitions, and thought suppression in obsessive-compulsive disorder.
    Besiroglu L; Çetinkaya N; Selvi Y; Atli A
    Compr Psychiatry; 2011; 52(5):556-61. PubMed ID: 21109243
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Obsessive-compulsive spectrum disorders: effective treatment with paroxetine.
    Ravindran AV; Lapierre YD; Anisman H
    Can J Psychiatry; 1999 Oct; 44(8):805-7. PubMed ID: 10566112
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacologic management of obsessive-compulsive disorder.
    Jackson CW; Morton WA; Lydiard RB
    South Med J; 1994 Mar; 87(3):310-21. PubMed ID: 8134850
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bipolar co-morbidity in pediatric obsessive-compulsive disorder: clinical and treatment implications.
    Masi G; Perugi G; Millepiedi S; Toni C; Mucci M; Pfanner C; Berloffa S; Pari C; Akiskal HS
    J Child Adolesc Psychopharmacol; 2007 Aug; 17(4):475-86. PubMed ID: 17822342
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Obsessive-compulsive disorder-related disorders: the role of selective serotonergic reuptake inhibitors.
    Hollander E
    Int Clin Psychopharmacol; 1996 Dec; 11 Suppl 5():75-87. PubMed ID: 9032004
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.